SUPPLEMENTARY INFORMATION

A GFP-tagged nucleoprotein-based aggregation assay for anti-Influenza drug discovery and antibody development

Helma Antony[1,2,3] and **Patrick M. Schaeffer***[1,2,3]

[1]Centre for Biodiscovery and Molecular Development of Therapeutics, James Cook University, Douglas, QLD 4811, Australia

[2]Comparative Genomics Centre, School of Pharmacy and Molecular Sciences, James Cook University, Douglas, QLD 4811, Australia

[3]School of Pharmacy and Molecular Sciences, James Cook University, Douglas, QLD 4811, Australia



Figure S1. Kinetic plot of NP-GFP aggregation with increasing concentrations (2, 4, 20, 40 µM) of nucleozin. Reactions were incubated at RT for 0, 1 and 16 h. Residual fluorescence was measured in the reaction supernatants.

Table S1. Values of F_{sol} obtained upon nucleozin treatment to protein mixture. (see Fig. 2C)

	F_{sol} ± SD (n=3)			
Nucleozin (μM)	NP-GFP *(Densitometric)*	Control *(Densitometric)*	NP *(Densitometric)*	GFP *(Densitometric)*
0	1.00 ± 0.00	1.00 ± 0.00	1.00 ± 0.00	1.00 ± 0.00
2	0.55 ± 0.03	0.99 ± 0.20	0.26 ± 0.03	0.97 ± 0.01
4	0.30 ± 0.04	0.98 ± 0.28	0.08 ± 0.01	0.99 ± 0.04
20	0.06 ± 0.01	0.80 ± 0.30	0.01 ± 0.01	0.98 ± 0.04
40	0.04 ± 0.01	0.88 ± 0.31	0.01 ± 0.01	1.01 ± 0.06

Table S2. Values of F_{sol} obtained upon nucleozin treatment to individual proteins (see Fig. 2D)

	F_{sol} ± SD (n=3)		
Nucleozin (μM)	NP-GFP *(Densitometric)*	NP *(Densitometric)*	NP-GFP *(Fluorimetric)*
0	1.00 ± 0.00	1.00 ± 0.00	1.00 ± 0.00
2	0.35 ± 0.06	0.34 ± 0.05	0.40 ± 0.02
4	0.25 ± 0.02	0.15 ± 0.03	0.36 ± 0.03
20	0.12 ± 0.02	0.01 ± 0.01	0.22 ± 0.03
40	0.07 ± 0.02	0.00 ± 0.01	0.19 ± 0.01